Skip to main navigation Skip to search Skip to main content

A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple...

Project: Research

Project Details

StatusFinished
Effective start/end date03/28/23 → 09/30/26

Funding

  • Fortrea Incorporated: $120,797.50